GR3032828T3 - Injectable taxane derivative based compositions. - Google Patents

Injectable taxane derivative based compositions.

Info

Publication number
GR3032828T3
GR3032828T3 GR990401833T GR990401833T GR3032828T3 GR 3032828 T3 GR3032828 T3 GR 3032828T3 GR 990401833 T GR990401833 T GR 990401833T GR 990401833 T GR990401833 T GR 990401833T GR 3032828 T3 GR3032828 T3 GR 3032828T3
Authority
GR
Greece
Prior art keywords
based compositions
taxane derivative
derivative based
injectable
solutions
Prior art date
Application number
GR990401833T
Other languages
Greek (el)
English (en)
Inventor
Jean-Marc Bobee
Lanty Patrick De
Gilles Guerin
Michel Veillard
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9436137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3032828(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of GR3032828T3 publication Critical patent/GR3032828T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Detergent Compositions (AREA)
GR990401833T 1992-12-02 2000-03-23 Injectable taxane derivative based compositions. GR3032828T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9214501A FR2698543B1 (fr) 1992-12-02 1992-12-02 Nouvelles compositions à base de taxoides.
PCT/FR1993/001166 WO1994012171A1 (fr) 1992-12-02 1993-11-26 Compositions injectables a base de derives des taxanes

Publications (1)

Publication Number Publication Date
GR3032828T3 true GR3032828T3 (en) 2000-06-30

Family

ID=9436137

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401833T GR3032828T3 (en) 1992-12-02 2000-03-23 Injectable taxane derivative based compositions.

Country Status (28)

Country Link
US (1) US5438072A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0671912B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3689791B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100330316B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN1291713C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE190838T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU691476B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2150576C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ284080B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE69328192D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0671912T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2145115T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI113619B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2698543B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP19991856B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3032828T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU222833B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9306986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO314436B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ258150A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL174334B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT671912E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2144356C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK281558B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW271395B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994012171A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU49092B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA938936B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
DK2226085T3 (da) 1993-07-19 2014-02-03 Angiotech Pharm Inc Anti-angiogene sammensætninger samt fremgangsmåder til anvendelse deraf
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
DE19655141C5 (de) 1996-11-08 2013-12-05 Eppendorf Ag Gradienten-Temperierblock für Laborthermostaten
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
DE69737510T2 (de) 1996-12-30 2007-12-06 Battelle Memorial Institute, Columbus Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
WO1998049321A2 (en) 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
ATE226070T1 (de) * 1997-05-30 2002-11-15 Man Woo Han Taxol enthaltende pharmazeutische injektionslösung
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
IL149488A0 (en) * 1999-11-15 2002-11-10 Pharma Mar Sa Pharmaceutical compositions containing aplidine
MXPA01009900A (es) * 2000-02-02 2003-08-20 Univ Florida State Res Found Formulaciones de taxano que tienen solubilidad mejorada.
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20040241094A1 (en) * 2001-09-13 2004-12-02 Hesson Chung Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
EP1435991B1 (en) * 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CN100341589C (zh) 2002-05-24 2007-10-10 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
ES2417324T3 (es) 2002-09-06 2013-08-07 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
WO2005051451A2 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
EP1792927B1 (en) 2004-09-22 2013-03-06 Nippon Kayaku Kabushiki Kaisha Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
EP2138164A1 (en) 2005-06-17 2009-12-30 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
WO2007111211A1 (ja) * 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha タキサン類の高分子結合体
RU2447095C2 (ru) 2006-05-18 2012-04-10 Ниппон Каяку Кабусики Кайся Высокомолекулярный конъюгат подофиллотоксинов
ES2584840T3 (es) * 2006-10-03 2016-09-29 Nippon Kayaku Kabushiki Kaisha Compuesto de un derivado de resorcinol con un polímero
EP2080779B1 (en) 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
AU2008205330B2 (en) 2007-01-08 2014-07-03 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services SLCO1B3 genotype
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
US20080319048A1 (en) * 2007-06-22 2008-12-25 Scidose Llc Solubilized formulation of docetaxel without tween 80
JP5349318B2 (ja) * 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
CN101396354B (zh) * 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
EP2205215A2 (en) * 2007-10-01 2010-07-14 Intas Pharmaceuticals Limited Docetaxel injectable composition, being absolutely free of ethanol
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
CA2717181C (en) 2008-03-14 2013-10-15 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
AU2008352603B2 (en) 2008-03-14 2012-05-31 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
KR101589582B1 (ko) * 2008-03-18 2016-01-28 니폰 가야꾸 가부시끼가이샤 생리활성물질의 고분자량 결합체
EP2644194B1 (en) 2008-03-18 2017-04-19 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
RU2428175C2 (ru) * 2008-06-02 2011-09-10 Закрытое Акционерное Общество "Биокад" Способ получения парентерального фармацевтического раствора
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
CN102159250B (zh) 2008-08-11 2014-08-06 尼克塔治疗公司 多臂的聚合烷酸酯偶联物
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2405941A1 (en) 2009-03-11 2012-01-18 Ambit Biosciences Corporation Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
EP2431403B1 (en) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymer conjugate of bioactive substance having hydroxy group
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
PH12012500848A1 (en) 2009-10-29 2016-02-08 Aventis Pharma Sa Novel antitumoral use of cabazitaxel
MX2012005987A (es) * 2009-11-23 2012-06-25 Cerulean Pharma Inc Polimeros a base de ciclodextrina para administracion terapeutica.
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
SG183361A1 (en) 2010-02-18 2012-09-27 Ct Nac Investigaciones Oncologicas Cnio Triazolo [4, 5 - b] pyridin derivatives
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
KR101752944B1 (ko) 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
WO2012067138A1 (ja) 2010-11-17 2012-05-24 日本化薬株式会社 新規なシチジン系代謝拮抗剤の高分子誘導体
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
EP2694485B1 (en) 2011-04-01 2017-11-15 Genentech, Inc. Combination of akt inhibitor compound and vemurafenib for use in therapeutic treatments
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
SG11201400681UA (en) 2011-05-19 2014-08-28 Ct Nac De Investigaciones Oncológicas Cnio Macrocyclic compounds as protein kinase inhibitors
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
SI2753355T1 (sl) 2011-09-08 2019-02-28 New York University Onkolitični virus herpesa simpleksa in njegove terapevtske uporabe
JP5711378B2 (ja) 2011-09-11 2015-04-30 日本化薬株式会社 ブロック共重合体の製造方法
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
CA2871359A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014149871A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
SG11201607746QA (en) 2014-03-21 2016-10-28 Abbvie Inc Anti-egfr antibodies and antibody drug conjugates
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
EP3307330B1 (en) 2015-06-15 2021-03-10 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
BR112018075653A2 (pt) 2016-06-08 2019-08-27 Abbvie Inc anticorpos anti-b7-h3 e conjugados anticorpo fármaco
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
WO2017214335A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3469000A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
MX2018015272A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
AU2018328532A1 (en) 2017-09-07 2020-04-23 Ningbo Combireg Pharmaceutical Technology Co., Ltd Pharmaceutical composition of docetaxel conjugate and preparation method
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4507217A (en) * 1983-03-07 1985-03-26 Lipid Specialties, Inc. Magnetic compositions and magnetic memory devices prepared therefrom
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
JP2919867B2 (ja) * 1989-09-27 1999-07-19 千寿製薬株式会社 抗腫瘍剤
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Also Published As

Publication number Publication date
ATE190838T1 (de) 2000-04-15
CZ284080B6 (cs) 1998-08-12
FI952680A0 (fi) 1995-06-01
FI952680L (fi) 1995-06-01
HK1075197A1 (en) 2005-12-09
ES2145115T3 (es) 2000-07-01
NO314436B1 (no) 2003-03-24
DK0671912T3 (da) 2000-07-03
KR100330316B1 (ko) 2002-11-04
TW271395B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-03-01
RU2144356C1 (ru) 2000-01-20
CZ142195A3 (en) 1995-10-18
CA2150576C (fr) 2005-06-21
CA2150576A1 (fr) 1994-06-09
HU222833B1 (hu) 2003-11-28
PL309197A1 (en) 1995-09-18
CN1090170A (zh) 1994-08-03
NO952151D0 (no) 1995-05-31
AU691476B2 (en) 1998-05-21
US5438072A (en) 1995-08-01
CN1291713C (zh) 2006-12-27
SK281558B6 (sk) 2001-05-10
WO1994012171A1 (fr) 1994-06-09
NZ258150A (en) 1996-11-26
HUT72650A (en) 1996-05-28
DE69328192D1 (de) 2000-04-27
GEP19991856B (en) 1999-12-06
DE69328192T4 (de) 2007-07-19
FR2698543B1 (fr) 1994-12-30
EP0671912B1 (fr) 2000-03-22
FR2698543A1 (fr) 1994-06-03
KR950703946A (ko) 1995-11-17
DE69328192T2 (de) 2000-09-28
ZA938936B (en) 1994-08-03
CN1636560A (zh) 2005-07-13
HU9501596D0 (en) 1995-08-28
YU49092B (sh) 2003-12-31
YU74593A (sh) 1996-08-13
NO952151L (no) 1995-05-31
JP3689791B2 (ja) 2005-08-31
AU5566994A (en) 1994-06-22
SK72595A3 (en) 1995-11-08
EP0671912A1 (fr) 1995-09-20
PL174334B1 (pl) 1998-07-31
FI113619B (fi) 2004-05-31
MX9306986A (es) 1995-01-31
ES2145115T4 (es) 2010-06-17
PT671912E (pt) 2000-06-30
JPH08503689A (ja) 1996-04-23

Similar Documents

Publication Publication Date Title
HU9501596D0 (en) Injectable taxane derivative based compositions
IL129068A0 (en) Sulfinic acid derivatives and their preparation and use
MX9602837A (es) Composiciones cosmeticas o farmaceuticas que contienen mangiferina o sus derivados.
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
ES2140961T3 (es) Nuevos derivados de 19-nor-pregneno.
MY106406A (en) Acryloyl substituted pyrrole derivatives.
MY117090A (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
EP0460062A4 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
ES475633A1 (es) Procedimiento para la obtencion de derivados de 1-n-4,6-di-0-(aminoglicosil)-1,3-diamino-ciclitol.
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
IL127379A0 (en) Dihydrobenzopyran and related compounds useful as anti-inflammatory agents
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
ES2174113T3 (es) Nuevos derivados de ((3-alcoxi-fenoxi)-etil)-dialquilamina y su utilizacion como anestesicos locales.
BG103735A (en) Method for the preparation of substituted thiazolidindions
CA2010982A1 (en) Osteogenesis promotion with use of vitamin d derivatives
FI884838A0 (fi) Nytt s-timololderivat och foerfarande foer dess framstaellning.
GR78774B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY101896A (en) New tetracyclic indole derivatives
DE69620762D1 (de) Cardiotropische radiopharmazeutika,die einen übergangsmetall-nitrid-komplex enthalten und die eine rasche myocardial-eliminierung aufweisen
EP0654269A4 (en) MEDICAL COMPOSITION FOR INHIBITING CANCER METASAS IN LIVER AND MEDICAL COMPOSITION FOR TREATING THE HEPATOMA.
BG95629A (en) Derivatives of 10, 11, 12, 13 - tetrahytdrodesmicozine, method for preparing them, and their use as pharmaceutical preparations
GB1250209A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB1504207A (en) Compositions containing p-alkanoyltoluene derivatives